Bios Capital Management, LP In8 Bio, Inc. Call Options Transaction History
Bios Capital Management, LP
- $79.2 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INAB
# of Institutions
29Shares Held
21.7MCall Options Held
0Put Options Held
0-
Franklin Resources Inc San Mateo, CA5.7MShares$854,4300.0% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL2.08MShares$311,9360.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.8MShares$270,4430.0% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.45MShares$217,5000.13% of portfolio
-
Sigma Planning Corp Ann Arbor, MI701KShares$105,1020.0% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $3.68M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...